Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers break chain of biochemical events that brain cancer cells use to evade therapy

07.02.2006


In their quest to find and exploit vulnerabilities in the natural armor that protects malignant brain tumors from destruction, researchers have found a way to decrease the cells¡¦ resistance to therapies that are designed to trigger cell death. The findings resulted from laboratory experiments conducted at Cedars-Sinai Medical Center’s Maxine Dunitz Neurosurgical Institute and are based on the manipulation of a series of intricate biochemical events taking place within brain tumor cells.

"We have described and are exploiting a biochemical pathway to make brain cancers much more sensitive to common therapeutic agents that cause a natural process of cell death called apoptosis," said John S. Yu, M.D., co-director of the Comprehensive Brain Tumor Program at the Institute, adding that the researchers are applying for Food and Drug Administration approval to translate their findings into patient clinical trials as soon as possible.

Although most types of cells can be dismantled and cleared by apoptosis a "programmed" and necessary cell death mechanism gliomas and other cancer cells have genes that enable them to thwart apoptosis and continue to grow unchecked even when subjected to therapies that are designed to initiate or enhance apoptosis.



One such therapy, which Institute researchers have studied and are developing, centers on a protein called TRAIL (tumor necrosis factor related apoptosis inducing ligand). TRAIL has been shown to cause cell death in several types of cancers, with negligible damage to normal cells. The new findings should increase the effectiveness of TRAIL and other agents that trigger a "caspase cascade" a specific biochemical chain reaction resulting in cell death.

In the normal process of apoptosis, the enzymes caspase-8 and caspase-9 activate caspase-3, which initiates cell breakdown, leading to cell death. In gliomas, however, several proteins that modulate these enzymes are overexpressed, resulting in down-regulation (reduction) of enzyme activity. With caspase-3 activation blocked, apoptosis is halted and cancer cells grow uncontrolled.

The Cedars-Sinai researchers theorized that a diabetes drug called troglitazone would limit the effects of the overexpressed proteins, reinstating the caspase activity and the process of apoptosis. In patient trials, pioglitazone will be used instead of troglitazone, which was the ingredient in Rezulin„¥, removed from the market because of safety issues. Pioglitazone acts in cancer cells in the same way as troglitazone, but without the associated liver concerns. Both are in a family of drugs called thiazolidinediones, given in tablet form to patients with Type 2 diabetes to improve cells’ responsiveness to insulin.

Although Yu and his colleagues usually are hesitant to prescribe more than one anti-cancer medication, this appears to be an ideal situation for a two-drug attack.

"When you combine two therapeutic agents, you usually get the toxicity of both, which is additive. But this strategy is different in that we are using a common diabetes drug that does not have the toxicity of a therapeutic agent. We have medications that are designed to induce apoptosis in tumor cells. Now we have a drug that appears to lower thresholds for induction of apoptosis," said Yu, senior author of a paper describing the study in the Journal of Biological Chemistry, published online Nov. 30, 2005. The article is expected to be published in the print version of the journal in late January.

"This study shows that as we begin to dissect the biochemistry of cancer, we can design therapies that interact within the critical pathways that are important for cancers to survive," said Keith L. Black, M.D., director of the Institute and the Division of Neurosurgery at Cedars-Sinai. "One of the things we have learned is that there probably will not be one ultimate pathway in cancer that we can block and be curative. A more likely scenario is that we will need to develop multiple pathways for interaction. The understanding we gain from translating basic research into patient care allows us to build upon what we already know and begin to block additional pathways to make our current therapies more effective."

Sandy Van | EurekAlert!
Further information:
http://www.csmc.edu/

More articles from Life Sciences:

nachricht A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich

nachricht New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Switched-on DNA

20.02.2017 | Materials Sciences

Second cause of hidden hearing loss identified

20.02.2017 | Health and Medicine

Prospect for more effective treatment of nerve pain

20.02.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>